B

Bioton SA
WSE:BIO

Watchlist Manager
Bioton SA
WSE:BIO
Watchlist
Price: 4.01 PLN -0.25%
Market Cap: zł344.3m

Net Margin

-1%
Current
Improving
by 0.8%
vs 3-y average of -1.7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1%
=
Net Income
zł-2.8m
/
Revenue
zł295.8m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1%
=
Net Income
zł-2.8m
/
Revenue
zł295.8m

Peer Comparison

Country Company Market Cap Net
Margin
PL
Bioton SA
WSE:BIO
345.2m PLN
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
173.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

In line with most companies in Poland
Percentile
35th
Based on 886 companies
35th percentile
-1%
Low
-9 940 700% — -3.7%
Typical Range
-3.7% — 9.1%
High
9.1% — 196 605.3%
Distribution Statistics
Poland
Min -9 940 700%
30th Percentile -3.7%
Median 2.9%
70th Percentile 9.1%
Max 196 605.3%

Bioton SA
Glance View

Market Cap
344.3m PLN
Industry
Biotechnology

BIOTON SA engages in the manufacture and production of medicine and pharmaceutical substances. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 371 full-time employees. The company went IPO on 2005-03-16. The firm is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The firm's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.

BIO Intrinsic Value
5.83 PLN
Undervaluation 31%
Intrinsic Value
Price
B
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-1%
=
Net Income
zł-2.8m
/
Revenue
zł295.8m
What is Bioton SA's current Net Margin?

The current Net Margin for Bioton SA is -1%, which is above its 3-year median of -1.7%.

How has Net Margin changed over time?

Over the last 3 years, Bioton SA’s Net Margin has increased from -2% to -1%. During this period, it reached a low of -7.5% on Dec 31, 2024 and a high of 2% on Mar 31, 2023.

Back to Top